Showing 1651-1660 of 23120 results for "".
Outcomes for PDR Patients LTFU for at Least 1 Year
https://reachmd.com/programs/new-retina-radio/outcomes-for-pdr-patients-ltfu-for-at-least-1-year/48969/How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joined by Matt Starr, MD, and Nita Valikodath, MD, MS, to explore a recent paper that leveraged the power the IRIS Registry to assess real-world outcomes for this imAdvocating for HS Patients
https://practicaldermatology.com/series/c-suite-chats/advocating-for-hs-patients/54617/Camille Lee, Head of US Immunology at UCB, discusses how her company has worked to elevate the hidradenitis suppurativa (HS) community and what it means to be patient-centric.Why Adenoma Detection Rate Matters in Colorectal Cancer Screening
https://reachmd.com/programs/clinicians-roundtable/adenoma-detection-rate-crc-screening/54722/New evidence from a report published in Gastroenterology demonstrates that higher adenoma detection rates (ADR) are directly associated with improved colorectal cancer detection, reinforcing ADR as a critical quality metric. Learn more about this study and its implications for optimizing screening qAssessing Quality of Life in Autoimmune Liver Diseases
https://reachmd.com/programs/gi-insights/assessing-quality-of-life-in-autoimmune-liver-diseases/49145/Autoimmune liver diseases, particularly primary biliary cholangitis, can significantly impact patients’ health-related quality of life through symptoms like fatigue and pruritus. Understanding how these symptoms affect daily functioning is critical for improving patient-centered care and treatment sWhy Molecular Testing Matters in Non-Small Cell Lung Cancer
https://reachmd.com/programs/project-oncology/why-molecular-testing-matters-in-non-small-cell-lung-cancer/49127/Targeted therapies have transformed what’s possible for patients with non-small cell lung cancer (NSCLC), but only if we take full advantage of molecular testing. Hear Dr. Geoffrey Oxnard discuss why both access to testing and belief in its value matter, and how clinicians can thoughtfully incorporaAdvancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
https://reachmd.com/programs/neurofrontiers/ms-multimodal-aging-signatures-proteomic-biomarkers/54241/Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS,The Science and Art of Longevity in Aesthetics
https://modernaesthetics.com/topics/skincare/the-science-and-art-of-longevity-in-aesthetics/35426/A panel discussion at Octane Aesthetic Tech ForumPatient Selection and Assessment
https://reachmd.com/programs/modern-aesthetics/Patient-Selection-Assessment/32707/Aesthetic treatment outcomes are dependent on a number of factors, including the products that are used and the clinician’s skill level. Perhaps just as important—or even more so—is patient selection. Modern Aesthetics® convened an expert roundtable to discuss physical and mental considerations, howThe Expanding Role of Peripheral Nerve Stimulation in Acute Pain Control
https://reachmd.com/programs/clinicians-roundtable/the-expanding-role-of-peripheral-nerve-stimulation-in-acute-pain-control/26728/Tune in to learn more about the role of peripheral nerve stimulation in acute pain management.Strategies for Addressing Diabetes Stigma and Discrimination
https://reachmd.com/programs/diabetes-discourse/strategies-for-addressing-diabetes-stigma-and-discrimination/16367/Tune in to learn about the stigma and discrimination patients with diabetes can face and how we as healthcare providers can reduce that burden.